Abatacept was the only biologic with a point estimate trending toward lower infection risk than control (OR, 0.57; 95% CI, 0.30–1.08), ADA was among the seven biologics showing a nonsignificant trend toward higher infection risk (OR, 1.12; 95% CI, 0.73–1.70), while certolizumab was the only agent with a statistically significant increase in risk (OR, 3.51; 95% CI, 1.59–7.79).
← all excerpts
The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agents.
2
—
—
The sentences
Even patients with total spinal ankylosis achieved ASAS20 responses at week 12 (in three of six cases, compared with zero of five cases for PBO), although the low patient numbers did not reach statistical significance.